CU-CPT9b 是 TLR8 的特异性拮抗剂，其 IC₅₀ 值为 0.7 nM。CU-CPT9b 高亲和性结合 TLR8， K_d 值为 21 nM。

CU-CPT9b is a specific TLR8 antagonist, with an IC 50 of 0.7 nM. CU-CPT9b shows high binding affinity towards TLR8 with a K d of 21 nM.

Solid

TLR8 0.7 nM (IC50) TLR8 21 nM (Kd)

CU-CPT9b is a specific TLR8 antagonist, with an IC50 of 0.7±0.2 nM. ITC experiments have confirmed the strong binding of CU-CPT9b with a Kd of 21 nM. It is shown that CU-CPT-9b binds to the inactive TLR8 dimer in a similar way to CU-CPT8m. CU-CPT9b utilizes hydrogen bonds with G351 and V520*, which are conserved among TLR8/antagonist structures. Additionally, CU-CPT9b forms water-mediated contacts with S516* and Q519*, which are not observed in TLR8/CU-CPT8m structure, suggesting that the enhanced potency of CU-CPT9b derives from the new interactions with these polar residues. The orientation of Y567* also changes to facilitate van der Waals interactions with CU-CPT9b as compared to TLR8/CU-CPT8m. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018 Jan;14(1):58-64.

In Vitro: DMSO : 83.33 mg/mL (331.62 mM; Need ultrasonic)配制储备液